Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
84 hedge funds and large institutions have $624M invested in Adaptimmune Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 17 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
0.11% less ownership
Funds ownership: 12.74% → 12.62% (-0.11%)
2% less capital invested
Capital invested by funds: $637M → $624M (-$13.3M)
3% less funds holding
Funds holding: 87 → 84 (-3)
11% less call options, than puts
Call options by funds: $982K | Put options by funds: $1.11M
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$6.35M |
| 2 |
Rafferty Asset Management
New York
|
+$5.06M |
| 3 |
JP Morgan Chase
New York
|
+$3.76M |
| 4 |
OAMG
Odey Asset Management Group
London,
United Kingdom
|
+$3.15M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.5M |
| 2 |
Renaissance Technologies
New York
|
-$4.53M |
| 3 |
Morgan Stanley
New York
|
-$3.8M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.52M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.16M |
ADAP Hedge Fund Activity: Q1 2021 in Review
84 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2021, worth a combined $624M — down 2.1% from $637M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ADAP and 15 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 28 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $6.35M. The largest seller was RA Capital Management, exiting entirely with an estimated $13.5M sold.
- 84 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2021, down from 87 in Q4 2020.
- Funds reported $624M of Adaptimmune Therapeutics stock for Q1 2021, down 2.1% quarter-over-quarter.
- 15 funds opened new Adaptimmune Therapeutics positions in Q1 2021 and 17 closed out, a net change of -2 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2021 was Baillie Gifford & Co, an estimated $6.35M added.
- The largest Adaptimmune Therapeutics seller in Q1 2021 was RA Capital Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q1 2021.